BMS Jumps Ahead With LAG-3 Melanoma Data
Early Data Suggest Potential For New IO/IO Pairing
LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.
